Impaired platelet function and peripartum bleeding in women with Gaucher disease

Summary

The risk of bleeding during delivery may be increased in women with Gaucher disease. We aimed to evaluate potential predictors for peripartum haemorrhage (PPH) during childbirth in these patients, while focusing upon coagulation tests and platelet function assays. Women with type 1 Gaucher disease who gave birth at Sheba Medical Center between 1999–2009 comprised the study cohort. Data collected included disease history, enzyme treatment, platelet counts, delivery and pregnancy outcome. PPH was defined as excessive bleeding during or immediately following delivery. Coagulation studies and platelet function tests, including aggregometry and cone and platelet (CPA) analyses, were performed on all women. We compared women with PPH (bleeders) and non-bleeders. Furthermore, women with abnormal CPA platelet function tests were compared with those with normal CPA platelet function with regards to the risk for PPH in at least one pregnancy. Forty-five pregnancies of 20 women were studied. Six women received enzyme replacement therapy during pregnancy. Mean platelet count prior to delivery was 83,000/μl ± 35,000/μl. Fourteen out of 45 (31%) deliveries were complicated by PPH. Neither thrombocytopenia nor enzyme therapy predicted PPH. Twelve out of 13 women with PPH (92.3%) versus 2/7 non-bleeders (28.6%) had impaired platelet aggregation (less than the 3^rd percentile of normal average aggregate size values), when tested by CPA, (odds ratio [OR] 17.8, 95% confidence interval [CI] 2.5; 126.2; p=0.007). Notably, 78.6% of women with impaired CPA aggregation developed PPH during at least one delivery, as opposed to 16.7% of those with normal CPA platelet function tests (OR 11.6, 95% CI 1.7–77.7, p=0.018). In conclusion, women with type 1 Gaucher disease who have abnormal platelet function tests may have an increased risk of PPH.

Keywords

Type 1 Gaucher disease - peripartum bleeding - PPH - platelet function - Cone and platelet analyzer (CPA)

• References

• 1 Beutler E, Grabowski GA. Gaucher Disease. In: The Metabolic and Molecular Bases of Inherited Diseases. 2001. (3^rd edition). New York: McGraw-Hill; pp. 3635-3668.
• 2 Barton NW. et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher‘s disease. N Engl J Med 1991; 324: 1464-1470.
• 3 Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129: 178-188.
• 4 Zimran A, Altarescu G, Rudensky B. et al. Survey of hematological aspects of Gaucher disease. Hematology 2005; 10: 151-156.
• 5 Gillis S, Hyam E, Abrahamov A. et al. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 1999; 61: 103-106.
• 6 Giona F, Palumbo G, Amendola A. et al. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). J Thromb Haemost 2006; 4: 1831-1833.
• 7 American College of Obstetrics and Gynecology.. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 2006; 108: 1039-1047.
• 8 Kennet G, Lubetsky A, Shenkman B. et al. Cone and platelet analyzer (CPA): A new test for prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998; 101: 255-259.
• 9 Shenkman B, Einav Y, Salomon O. et al. Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]. Platelets 2008; 19: 440-446.
• 10 Burtelow M, Riley E, Druzin M. et al. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. Transfusion 2007; 47: 1564-1572.
• 11 Oyelese Y, Scorza WE, Mastrolia R. et al. Postpartum hemorrhage. Obstet Gynecol Clin N Am 2007; 34: 421-441.
• 12 Combs CA, Murphy EL, Laros Jr. RK. Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol 1991; 77: 69-76.
• 13 Combs CA, Murphy EL, Laros Jr. RK. Factors associated with hemorrhage in cesarean deliveries. Obstet Gynecol 1991; 77: 77-82.
• 14 Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 1993; 48: 15-18.
• 15 Elstein Y, Eisenberg J, Granovsky-Grisaru S. et al. Pregnancy in Gaucher patients: A 5 year study. Am J Obstet Gynecol 2004; 190: 435-441.
• 16 Weinreb NJ, Charrow J, Andersson HC. et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113: 112-119.
• 17 Grabowski GA, Kacena K, Cole JA. et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009; 11: 92-100.
• 18 Sagdilek E, Buyukcoskun NI, Ozluk K. Evaluation of platelet function and lack of response to epinephrine in pregnant women. Int J Lab Hem 2007; 29: 302-309.
• 19 Vincelot A, Nathan N, Collet D. et al. Platelet function during pregnancy: an evaluation using the PFA-100 analyser. Br J Anaesth 2001; 87: 890-893.
• 20 Hayashi M, Kiumi F, Mitsuya K. Changes in platelet ATP secretion and aggregation during pregnancy and preeclampsia. Am J Med Sci 1999; 318: 115-121.
• 21 Karalis I, Nadar SK, Al Yemeni E. et al. Platelet activation in pregnancy-induced hypertension. Thromb Res 2005; 116: 377-383.
• 22 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
• 23 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 24 Panzer S, Rieger M, Vormittag R. et al. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007; 37: 814-819.
• 25 Bolton-Maggs PH. Factor XI deficiency. Baillieres Clin Haematol 1996; 9: 355-368.
• 26 Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-493.
• 27 Salomon O, Steinberg DM, Tamarin I. et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
• 28 Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988; 319: 142-145.